首页 | 本学科首页   官方微博 | 高级检索  
检索        

超声造影检查在肾肿瘤射频消融术后疗效评估中的应用价值
引用本文:张炜炜,孔文韬,邱君斓,郭宏骞,李笑弓,甘卫东,蒋智明,沈祎,张士伟.超声造影检查在肾肿瘤射频消融术后疗效评估中的应用价值[J].中华泌尿外科杂志,2011,32(1).
作者姓名:张炜炜  孔文韬  邱君斓  郭宏骞  李笑弓  甘卫东  蒋智明  沈祎  张士伟
作者单位:1. 南京大学医学院附属鼓楼医院外科超声室,210008
2. 南京大学医学院附属鼓楼医院泌尿外科,210008
摘    要:目的 探讨实时超声造影(CEUS)检查在肾肿瘤射频消融(RFA)术后疗效评估中的作用.方法 对47例肾肿瘤患者(肾癌40例,肾血管平滑肌脂肪瘤7例)49个病灶行RFA治疗,其中经腹腔镜下RFA 30例,开放手术RFA 17例.术后1周行常规超声及CEUS检查,观察造影剂在动脉相与实质相的灌注情况,评价病灶消融范围,并与增强CT结果比较.影像学上病灶无增强被认为是消融完全. 结果 49个病灶完全消融47个(95.9%).CEUS显示肾消融灶最大径为2.4~10.0 cm,平均(4.6±1.5)cm,其中消融灶大于原病灶者45个、与原病灶相同者3个、小于原病灶者1个.CEUS提示RFA术后原病灶有局部强化6例,其中2例经增强CT证实.以增强CT结果作为诊断标准,CEUS对RFA术后残留灶诊断的敏感性为100.0%,特异性为91.8%.术后平均随访11(4~21)个月,患者均存活. 结论 CEUS检查与CT结合对评价肾肿瘤RFA术后疗效具有实用价值.
Abstract:
Objective To discuss the utility of contrast-enhanced ultrasonography (CEUS) in the assessment of treatment efficacy of radiofrequency ablation (RFA) in patients with renal tumors.Methods Forty-seven patients (40 renal cell carcinomas and 7 angiomyolipomas of kidney) with 49 renal tumors were treated with RFA. Tumors were ablated by laparoscopy-assisted (n= 30) and open surgical (n= 17) RFA. The CEUS and contrast-enhanced CT were performed 1 week after treatment to assess the necrotic area. Technical success was defined as elimination of areas that enhanced at imaging within the entire tumor. Results Forty-seven (95. 9%) of 49 tumors were successfully ablated. The mean length of the major axis at the maximal necrotic area was 4. 6 cm. Compared with the lesions before RFA, the necrotic areas were bigger in 45 patients, identical in 3 patients, and smaller in 1 patient. Six lesions showed a residual enhancement at the portion adjacent to the normal renal parenchyma on follow-up CEUS, while 2 were confirmed by CT scans. The sensitivity and specificity of CEUS for detection of residual tumors were 100. 0% and 91.8%, respectively. All patients survived in the follow-up period ranging from 4 to 21 months. Conclusion CEUS combined with CT could be useful for evaluating treatment efficacy of RFA for renal tumors.

关 键 词:超声检查  图像增强  肾肿瘤  射频消融  治疗结果

Assessment of treatment efficacy in radiofrequency ablation for renal tumors by contrast-enhanced ultrasonography
ZHANG Wei-wei,KONG Wen-tao,QIU Jun-lan,GUO Hong-qian,LI Xiao-gong,GAN Wei-dong,JIANG Zhi-ming,SHEN Yi,ZHANG Shi-wei.Assessment of treatment efficacy in radiofrequency ablation for renal tumors by contrast-enhanced ultrasonography[J].Chinese Journal of Urology,2011,32(1).
Authors:ZHANG Wei-wei  KONG Wen-tao  QIU Jun-lan  GUO Hong-qian  LI Xiao-gong  GAN Wei-dong  JIANG Zhi-ming  SHEN Yi  ZHANG Shi-wei
Abstract:Objective To discuss the utility of contrast-enhanced ultrasonography (CEUS) in the assessment of treatment efficacy of radiofrequency ablation (RFA) in patients with renal tumors.Methods Forty-seven patients (40 renal cell carcinomas and 7 angiomyolipomas of kidney) with 49 renal tumors were treated with RFA. Tumors were ablated by laparoscopy-assisted (n= 30) and open surgical (n= 17) RFA. The CEUS and contrast-enhanced CT were performed 1 week after treatment to assess the necrotic area. Technical success was defined as elimination of areas that enhanced at imaging within the entire tumor. Results Forty-seven (95. 9%) of 49 tumors were successfully ablated. The mean length of the major axis at the maximal necrotic area was 4. 6 cm. Compared with the lesions before RFA, the necrotic areas were bigger in 45 patients, identical in 3 patients, and smaller in 1 patient. Six lesions showed a residual enhancement at the portion adjacent to the normal renal parenchyma on follow-up CEUS, while 2 were confirmed by CT scans. The sensitivity and specificity of CEUS for detection of residual tumors were 100. 0% and 91.8%, respectively. All patients survived in the follow-up period ranging from 4 to 21 months. Conclusion CEUS combined with CT could be useful for evaluating treatment efficacy of RFA for renal tumors.
Keywords:Ultrasonography  Imge enhancement  Kidney neoplasms  Radiofrequency ablation  Treatment outcome
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号